Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prism Medico & PharmacyBOM:512217 -3.38%55 Altman Z2-Score is 87.55 as of Jul. 25, 2026, which is 50% above its 10-year median of 58.37. GuruFocus rates BOM:512217 with a GF Score™ of 55/100 and a GF Value™ of ₹27.60 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,957 Consumer Packaged Goods companies, Prism Medico & Pharmacy ranks better than 99.54% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Prism Medico & Pharmacy has a Altman Z2-Score of 87.55, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Prism Medico & Pharmacy's Altman Z2-Score or its related term are showing as below:
BOM:512217'
s Altman Z2-Score Range Over the Past 10 Years
Min: 4.83 Med: 58.37 Max: 765.49
Current: 87.55
During the past 13 years, Prism Medico & Pharmacy's highest Altman Z2-Score was 765.49. The lowest was 4.83. And the median was 58.37.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:512217 vs ADM, BG, TSN: Altman Z2-Score Comparison
For the Farm Products subindustry, Prism Medico & Pharmacy's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prism Medico & Pharmacy Altman Z2-Score vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Prism Medico & Pharmacy's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Prism Medico & Pharmacy's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Prism Medico & Pharmacy (BOM:512217) has a Altman Z2-Score of 87.55 as of Jul. 25, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Prism Medico & Pharmacy and its competitors. This is 50% above median its historical median of 58.37. Over the past decade, Prism Medico & Pharmacy's Altman Z2-Score has ranged from 4.83 to 765.49. According to the industry distribution chart, Prism Medico & Pharmacy ranks #9 out of 1957 companies in the Consumer Packaged Goods industry, placing it in the top 0.5%.
Is Prism Medico & Pharmacy's Altman Z2-Score too high?
Prism Medico & Pharmacy's current Altman Z2-Score of 87.55 is 50% above median its 10-year median of 58.37. Over the past 10 years, this metric has ranged from a low of 4.83 to a high of 765.49. The Consumer Packaged Goods industry median Altman Z2-Score is 3.74. Prism Medico & Pharmacy's value of 87.55 is 2240.9% above this industry median. Based on the distribution chart, Prism Medico & Pharmacy ranks #9 out of 1957 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Prism Medico & Pharmacy has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Prism Medico & Pharmacy's Altman Z2-Score compare to ADM and BG?
According to the Consumer Packaged Goods industry distribution chart, Prism Medico & Pharmacy ranks #9 out of 1957 companies for Altman Z2-Score. This places Prism Medico & Pharmacy in the top 1% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 3.74. Prism Medico & Pharmacy's value of 87.55 is 2240.9% above this benchmark. Historically, Prism Medico & Pharmacy's own Altman Z2-Score has ranged from 4.83 to 765.49 over the past decade. While the company's 10-year median is 58.37 vs. the industry median of 3.74, Prism Medico & Pharmacy has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Consumer Packaged Goods company?
The median Altman Z2-Score among Consumer Packaged Goods companies is 3.74, based on 1,957 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prism Medico & Pharmacy's current Altman Z2-Score of 87.55 is 2240.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Prism Medico & Pharmacy and its competitors. For the Consumer Packaged Goods industry, the median Altman Z2-Score is 3.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prism Medico & Pharmacy's current Altman Z2-Score is 87.55, which is 50% above median its own 10-year median of 58.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prism Medico & Pharmacy stock overvalued right now?
Based on GuruFocus' analysis, Prism Medico & Pharmacy (BOM:512217) is currently considered Fairly Valued. The stock's GF Value™ is ₹27.60, compared to a current price of ₹26.28 — trading 4.8% below its estimated fair value. The current Altman Z2-Score is 87.55, which is 50% above median its 10-year median of 58.37 and 2240.9% above the Consumer Packaged Goods industry median of 3.74. Prism Medico & Pharmacy's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Prism Medico & Pharmacy (BOM:512217), the current Altman Z2-Score is 87.55 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prism Medico & Pharmacy (BOM:512217) Overvalued in 2026?
Based on GuruFocus' analysis, Prism Medico & Pharmacy stock appears to be undervalued.
The current stock price of ₹26.28 is trading 4.8% below its estimated GF Value™ of ₹27.60.
GuruFocus considers Prism Medico & Pharmacy to be Fairly Valued.
Key valuation signals for BOM:512217:
Altman Z2-Score: 87.55 (50% above median its 10-year median of 58.37)
GF Value™: ₹27.60 vs. price of ₹26.28 (4.8% below fair value)
Industry Position: 2240.9% above the Consumer Packaged Goods median (#9 of 1957)
No single metric tells the full story. See the BOM:512217 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prism Medico & Pharmacy Ltd operates in the wholesale and retail of animal feed, poultry feed, cattle feed, aqua feed, ayurvedic foods, organic food, juices, cosmetics, herbal extracts, nutrients, and FMCG products. The company generates the majority of its revenue from the sale of agricultural products.
55GF Score
Get the complete analysis for BOM:512217
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:512217 has been successfully added to your 
